These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 35985917)
21. Serological surveys to estimate cumulative incidence of SARS-CoV-2 infection in adults (Sero-MAss study), Massachusetts, July-August 2020: a mail-based cross-sectional study. Snyder T; Ravenhurst J; Cramer EY; Reich NG; Balzer L; Alfandari D; Lover AA BMJ Open; 2021 Aug; 11(8):e051157. PubMed ID: 34404716 [TBL] [Abstract][Full Text] [Related]
22. Limitations introduced by a low participation rate of SARS-CoV-2 seroprevalence data. Pluss O; Campbell H; Pezzi L; Morales I; Roell Y; Quandelacy TM; Arora RK; Boucher E; Lamb MM; Chu M; Bärnighausen T; Jaenisch T Int J Epidemiol; 2023 Feb; 52(1):32-43. PubMed ID: 36164817 [TBL] [Abstract][Full Text] [Related]
23. SARS-CoV-2 Variant Tracking and Mitigation During In-Person Learning at a Midwestern University in the 2020-2021 School Year. Avendano C; Lilienfeld A; Rulli L; Stephens M; Barrios WA; Sarro J; Pfrender ME; Miranda ML JAMA Netw Open; 2022 Feb; 5(2):e2146805. PubMed ID: 35113163 [TBL] [Abstract][Full Text] [Related]
24. Assessment of Simulated Surveillance Testing and Quarantine in a SARS-CoV-2-Vaccinated Population of Students on a University Campus. Motta FC; McGoff KA; Deckard A; Wolfe CR; Bonsignori M; Moody MA; Cavanaugh K; Denny TN; Harer J; Haase SB JAMA Health Forum; 2021 Oct; 2(10):e213035. PubMed ID: 35977169 [TBL] [Abstract][Full Text] [Related]
25. Seroprevalence of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in a vulnerable population in France: a cross-sectional study. Beaumont A; Durand C; Ledrans M; Schwoebel V; Noel H; Le Strat Y; Diulius D; Colombain L; Médus M; Gueudet P; Mouly D; Aumaître H BMJ Open; 2021 Nov; 11(11):e053201. PubMed ID: 34815286 [TBL] [Abstract][Full Text] [Related]
26. Risk Management of COVID-19 in the Residential Educational Setting: Lessons Learned and Implications for Moving Forward. Cass AL; Slining MM; Carson C; Cassidy J; Epright MC; Gilchrist AE; Peterson K; Wheeler JF; The NS Int J Environ Res Public Health; 2021 Sep; 18(18):. PubMed ID: 34574668 [TBL] [Abstract][Full Text] [Related]
27. Seroprevalence of SARS-CoV-2 infection and associated factors among Bangladeshi slum and non-slum dwellers in pre-COVID-19 vaccination era: October 2020 to February 2021. Raqib R; Sarker P; Akhtar E; Nurul Huda TM; Haq MA; Roy AK; Hosen MB; Haque F; Chowdhury MR; Reidpath DD; Emdadul Hoque DM; Islam Z; Ahmed S; Ahmed T; Tofail F; Razzaque A PLoS One; 2022; 17(5):e0268093. PubMed ID: 35604947 [TBL] [Abstract][Full Text] [Related]
28. Seroprevalence of SARS-CoV-2 antibodies and associated risk factors in children less than 6 years of age in the canton of Fribourg, Switzerland (COVPED study): a population-based cross-sectional study. Rouge Elton PA; Schmitt PA; Faouzi M; Zimmermann P; Ritter Schenk C Swiss Med Wkly; 2022 May; 152():w30173. PubMed ID: 35748747 [TBL] [Abstract][Full Text] [Related]
29. Clustering and longitudinal change in SARS-CoV-2 seroprevalence in school children in the canton of Zurich, Switzerland: prospective cohort study of 55 schools. Ulyte A; Radtke T; Abela IA; Haile SR; Berger C; Huber M; Schanz M; Schwarzmueller M; Trkola A; Fehr J; Puhan MA; Kriemler S BMJ; 2021 Mar; 372():n616. PubMed ID: 33731327 [TBL] [Abstract][Full Text] [Related]
30. SARS-CoV-2 transmissions in students and teachers: seroprevalence follow-up study in a German secondary school in November and December 2020. Armann JP; Kirsten C; Galow L; Kahre E; Haag L; Dalpke A; Lück C; Berner R BMJ Paediatr Open; 2021; 5(1):e001036. PubMed ID: 34192197 [TBL] [Abstract][Full Text] [Related]
31. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study. Poustchi H; Darvishian M; Mohammadi Z; Shayanrad A; Delavari A; Bahadorimonfared A; Eslami S; Javanmard SH; Shakiba E; Somi MH; Emami A; Saki N; Hormati A; Ansari-Moghaddam A; Saeedi M; Ghasemi-Kebria F; Mohebbi I; Mansour-Ghanaei F; Karami M; Sharifi H; Pourfarzi F; Veisi N; Ghadimi R; Eghtesad S; Niavarani A; Ali Asgari A; Sadeghi A; Sorouri M; Anushiravani A; Amani M; Kaveh S; Feizesani A; Tabarsi P; Keyvani H; Markarian M; Shafighian F; Sima A; Sadjadi A; Radmard AR; Mokdad AH; Sharafkhah M; Malekzadeh R Lancet Infect Dis; 2021 Apr; 21(4):473-481. PubMed ID: 33338441 [TBL] [Abstract][Full Text] [Related]
32. SARS-CoV-2 seroprevalence and associated factors, based on HIV serostatus, in young people in Sofala province, Mozambique. Benoni R; Casigliani V; Zin A; Giannini D; Ronzoni N; Di Chiara C; Chhaganlal K; Donà D; Merolle A; Dos Anjos HG; Chenene F; Tognon F; Putoto G; Giaquinto C BMC Infect Dis; 2023 Nov; 23(1):809. PubMed ID: 37978353 [TBL] [Abstract][Full Text] [Related]
33. Demographic and occupational determinants of anti-SARS-CoV-2 IgG seropositivity in hospital staff. Martin CA; Patel P; Goss C; Jenkins DR; Price A; Barton L; Gupta P; Zaccardi F; Jerina H; Duraisingham S; Brunskill NJ; Khunti K; Pareek M J Public Health (Oxf); 2022 Jun; 44(2):234-245. PubMed ID: 33200200 [TBL] [Abstract][Full Text] [Related]
34. Seroprevalence of anti-SARS-CoV-2 antibodies in Iquitos, Peru in July and August, 2020: a population-based study. Álvarez-Antonio C; Meza-Sánchez G; Calampa C; Casanova W; Carey C; Alava F; Rodríguez-Ferrucci H; Quispe AM Lancet Glob Health; 2021 Jul; 9(7):e925-e931. PubMed ID: 34022148 [TBL] [Abstract][Full Text] [Related]
35. Assessment of initial SARS-CoV-2 seroprevalence in the most affected districts in the municipality of São Paulo, Brazil. Tess BH; Granato CFH; Alves MCGP; Pintão MCT; Nunes MC; Rizzatti EG; Reinach FC Braz J Infect Dis; 2021; 25(4):101604. PubMed ID: 34416142 [TBL] [Abstract][Full Text] [Related]
36. Alcohol risk management in college settings: the safer California universities randomized trial. Saltz RF; Paschall MJ; McGaffigan RP; Nygaard PM Am J Prev Med; 2010 Dec; 39(6):491-9. PubMed ID: 21084068 [TBL] [Abstract][Full Text] [Related]
37. Averting an Outbreak of SARS-CoV-2 in a University Residence Hall through Wastewater Surveillance. Corchis-Scott R; Geng Q; Seth R; Ray R; Beg M; Biswas N; Charron L; Drouillard KD; D'Souza R; Heath DD; Houser C; Lawal F; McGinlay J; Menard SL; Porter LA; Rawlings D; Scholl ML; Siu KWM; Tong Y; Weisener CG; Wilhelm SW; McKay RML Microbiol Spectr; 2021 Oct; 9(2):e0079221. PubMed ID: 34612693 [TBL] [Abstract][Full Text] [Related]
38. Assessment of a COVID-19 Control Plan on an Urban University Campus During a Second Wave of the Pandemic. Hamer DH; White LF; Jenkins HE; Gill CJ; Landsberg HE; Klapperich C; Bulekova K; Platt J; Decarie L; Gilmore W; Pilkington M; MacDowell TL; Faria MA; Densmore D; Landaverde L; Li W; Rose T; Burgay SP; Miller C; Doucette-Stamm L; Lockard K; Elmore K; Schroeder T; Zaia AM; Kolaczyk ED; Waters G; Brown RA JAMA Netw Open; 2021 Jun; 4(6):e2116425. PubMed ID: 34170303 [TBL] [Abstract][Full Text] [Related]
39. A Cross-Sectional Study Examining the Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies in a University Student Population. Tilley K; Ayvazyan V; Martinez L; Nanda N; Kawaguchi ES; O'Gorman M; Conti D; Gauderman WJ; Van Orman S J Adolesc Health; 2020 Dec; 67(6):763-768. PubMed ID: 33071164 [TBL] [Abstract][Full Text] [Related]
40. A Cross-Sectional Study of Exposure Factors Associated with Seropositivity for SARS-CoV-2 Antibodies during the Second Epidemic Wave among a Sample of the University of Corsica (France). Decarreaux D; Sevila J; Masse S; Capai L; Fourié T; Saba Villarroel PM; Amroun A; Nurtop E; Vareille M; Pouquet M; Blanchon T; de Lamballerie X; Charrel R; Falchi A Int J Environ Res Public Health; 2022 Feb; 19(4):. PubMed ID: 35206161 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]